Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update after the close of U.S. markets on Thursday, August 6, 2026, followed by a company presentation at 4:30 p.m. ET (1:30 p.m. PT).
Investors can access the event via live webcast on the Investors section of Xenon’s website or by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (international), using conference ID 5286122. According to Xenon Pharmaceuticals, a replay will be posted after the event and the timing is subject to change.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior earnings-date announcement, news_id 1048873, was followed by 0.16%. That comparison frames...
Analysis
The prior earnings-date announcement, news_id 1048873, was followed by 0.16%. That comparison frames this as a scheduling notice; recent insider activity was net selling, and the Q2 results and business update remain the substantive items to monitor.
Key Figures
Reporting date:August 6, 2026Presentation time:4:30pm ETAzetukalner development stage:Phase 3 clinical trials+1 more
4 metrics
Reporting dateAugust 6, 2026Q2 2026 financial results after U.S. market close
Presentation time4:30pm ETAugust 6, 2026 company presentation
Azetukalner development stagePhase 3 clinical trialsEpilepsy, major depressive disorder, and bipolar depression
Pain programs development stagePhase 1 developmentKV7 and NaV1.7 programs
Scheduled Q1 2026 results and business update for May 7
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The prior earnings-date announcement was followed by a 0.16% move, providing limited evidence of a strong directional pattern for this announcement type.
"azetukalner, is a novel, potent KV7 potassium channel opener"
Kv7 denotes a family of potassium ion channels in cell membranes that act like tiny gatekeepers controlling electrical signals in nerves and muscles; drugs that open or block these channels can change how cells fire. Investors care because Kv7 is a common drug target for conditions such as epilepsy, pain and some cardiac disorders, so breakthroughs or setbacks in Kv7-focused therapies can affect clinical progress, regulatory reviews and potential market value.
nav1.7medical
"including KV7 and NaV1.7 programs in Phase 1 development"
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.
phase 3 clinical trialsmedical
"is in Phase 3 clinical trials for the treatment of epilepsy"
Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
phase 1 developmentmedical
"NaV1.7 programs in Phase 1 development for the potential treatment of pain"
Phase 1 development is the first stage of testing a new drug or medical therapy in humans, focused on safety, how the body handles the treatment, and identifying a safe dose range. For investors it is an early milestone that reduces uncertainty—think of it like a prototype’s first test drive: passing it doesn’t prove long-term success but failing it can halt the program and materially affect a company’s value.
mddmedical
"major depressive disorder (MDD) and bipolar depression (BPD)"
Major depressive disorder (MDD) is a medical condition characterized by persistent low mood, loss of interest in daily activities, and impaired functioning similar to carrying a heavy backpack that makes ordinary tasks much harder. For investors, MDD matters because treatments and therapies for it are a large market regulated by health authorities; clinical trial outcomes, approvals, or safety concerns can strongly affect a drugmaker’s sales prospects, valuation, and risk profile.
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026.
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:
5286122
A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (Nasdaq: XENE) report its Q2 2026 earnings?
Xenon Pharmaceuticals will report its Q2 2026 financial results on Thursday, August 6, 2026, after U.S. markets close. According to Xenon Pharmaceuticals, the announcement will be accompanied by a business update and a webcasted company presentation that starts at 4:30 p.m. ET.
What time is the Xenon Pharmaceuticals (XENE) Q2 2026 earnings webcast on August 6, 2026?
The Xenon Pharmaceuticals Q2 2026 webcast is scheduled for 4:30 p.m. ET (1:30 p.m. PT) on August 6, 2026. According to Xenon Pharmaceuticals, the event follows the financial results release and includes a broader business update for investors.
How can investors access the Xenon Pharmaceuticals (XENE) Q2 2026 earnings call webcast and dial-in?
Investors can access the Q2 2026 Xenon Pharmaceuticals presentation via live webcast on the company’s Investors webpage. According to Xenon Pharmaceuticals, dial-in numbers are (800) 715-9871 toll-free or (646) 307-1963 for international callers, using conference ID 5286122.
Will a replay be available for the Xenon Pharmaceuticals (XENE) Q2 2026 earnings webcast?
Yes, a replay of the Xenon Pharmaceuticals Q2 2026 webcast will be posted after the event. According to Xenon Pharmaceuticals, investors will be able to access the replay through the Investors section of the company’s website following the August 6, 2026 presentation.
What therapies and clinical programs will Xenon Pharmaceuticals (XENE) likely discuss in its Q2 2026 update?
Xenon Pharmaceuticals may discuss azetukalner, its lead KV7 potassium channel opener in Phase 3 for epilepsy, MDD, and BPD. According to Xenon Pharmaceuticals, it is also advancing early-stage KV7 and NaV1.7 programs in Phase 1 development for potential pain treatment.
Where is Xenon Pharmaceuticals (XENE) headquartered and what is its therapeutic focus?
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company with offices in Vancouver, British Columbia, and Boston, Massachusetts. According to Xenon Pharmaceuticals, it develops potassium and sodium channel modulators, led by azetukalner in Phase 3 and several early-stage KV7 and NaV1.7 programs.
